The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Inhibition of P-Glycoprotein by Newer Antidepressants
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Fluorescent cellular indicators are extruded by the multidrug resistance protein.
Homolya, L., Holló, Z., Germann, U. A., Pastan, I., Gottesman, M. M., & Sarkadi, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80566-3 · Cited by 495
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Uhr, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00095-0 · Cited by 244
The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions
Yu, D. K. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922012006 · Cited by 199
In Vitro Approaches to Predicting Drug Interactions In Vivo
von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., Harmatz, J. S., & Shader, R. I. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00239-6 · Cited by 197
Transport properties of the multidrug resistance‐associated protein (MRP) in human tumour cells
Holló, Z., Homolya, L., Hegedüs, T., & Sarkadi, B. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00237-2 · Cited by 195
HMG‐CoA reductase inhibitors and P‐glycoprotein modulation
Bogman, K., Peyer, A., Török, M., Küsters, E., & Drewe, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703920 · Cited by 194
Feller, N., Broxterman, H. J., Währer, D. C. R., & Pinedo, H. M. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00677-2 · Cited by 192
Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay
Tiberghien, F., & Loor, F. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00012 · Cited by 187
Caccia, S. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834040-00002 · Cited by 175
Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein
Ekins, S., Kim, R. B., Leake, B. F., Dantzig, A. H., Schuetz, E. G., Lan, L.-B., Yasuda, K., Shepard, R. L., Winter, M. A., Schuetz, J. D., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.5.964 · Cited by 166
Sindrup, S. H., Brøsen, K., & Gram, L. F. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.24 · Cited by 151
The Functional Role of P-Glycoprotein in the Blood–Brain Barrier
van Asperen, J., Mayer, U., van Tellingen, O., & Beijnen, J. H. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9701364 · Cited by 138
THE PHARMACOLOGICAL ROLE OF P-GLYCOPROTEIN IN THE INTESTINAL EPITHELIUM
van Asperen, J., van Tellingen, O., & Beijnen, J. H. (1998) · Pharmacological Research · doi:10.1006/phrs.1998.0326 · Cited by 130
Huwyler, J., Drewe, J., Klusemann, C., & Fricker, G. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15619.x · Cited by 123
Kusuhara, H., Suzuki, H., & Sugiyama, Y. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970100b · Cited by 117
Eneroth, A., Åström, E., Hoogstraate, J. A., Schrenk, D., Conrad, S., Kauffmann, H.-M., & Gjellan, K. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00117-2 · Cited by 113
Pharmacokinetics of Selective Serotonin Reuptake Inhibitors: Clinical Relevance
Catterson, M. L., & Preskorn, S. (1996) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1996.tb00206.x · Cited by 111
Gollapudi, S., Kim, C. H., Tran, B.-N., Sangha, S., & Gupta, S. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050640 · Cited by 109
Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists
Csajka, C., Buclin, T., Brunner, H. R., & Biollaz, J. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732010-00001 · Cited by 96
Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium
Rochat, B., Baumann, P., & Audus, K. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01461-4 · Cited by 72
Brain Microvessel Endothelial Cell Culture Systems
Audus, K. L., Ng, L., Wang, W., & Borchardt, R. T. (1996) · Pharmaceutical biotechnology · doi:10.1007/978-1-4899-1863-5_13 · Cited by 64
(1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-164_1 · Cited by 47
Potential Role of P-Glycoprotein in Affecting Hepatic Metabolism of Drugs
Chiou, W. L., Chung, S. M., & Wu, T. C. (2000) · Pharmaceutical Research · doi:10.1023/a:1007570517183 · Cited by 44
Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?
Rameis, H. (1985) · PubMed · Cited by 24
Lack of Citalopram Effect on Oral Digoxin Pharmacokinetics
Larsen, F., Priskorn, M., & Overø, K. F. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010041 · Cited by 24
Ochs, H. R., Greenblatt, D. J., Verburg-Ochs, B., et al. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03243.x · Cited by 23
Cited by
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Metadata
- Authors
- Weiss, J., Dormann, S.-M. G., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., & Haefeli, W. E.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-04
- Volume
- 305
- Issue
- 1
- Pages
- 197-204
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2156270847
- Cited by
- 292
- References
- 35
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.